The protective role of peroxisome proliferator-activated receptor gamma in lipotoxic podocytes

Almudena G Carrasco, Adriana Izquierdo-Lahuerta*, Ángela M Valverde, Lan Ni, Elena Flores-Salguero, Richard J Coward, Gema Medina-Gómez*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

1 Citation (Scopus)
29 Downloads (Pure)

Abstract

Podocytes are specialized epithelial cells that maintain the glomerular filtration barrier. These cells are susceptible to lipotoxicity in the obese state and irreversibly lost during kidney disease leading to proteinuria and renal injury. PPARγ is a nuclear receptor whose activation can be renoprotective. This study examined the role of PPARγ in the lipotoxic podocyte using a PPARγ knockout (PPARγKO) cell line and since the activation of PPARγ by Thiazolidinediones (TZD) is limited by their side effects, it explored other alternative therapies to prevent podocyte lipotoxic damage. Wild-type and PPARγKO podocytes were exposed to the fatty acid palmitic acid (PA) and treated with the TZD (Pioglitazone) and/or the Retinoid X receptor (RXR) agonist Bexarotene (BX). It revealed that podocyte PPARγ is essential for podocyte function. PPARγ deletion reduced key podocyte proteins including podocin and nephrin while increasing basal levels of oxidative and ER stress causing apoptosis and cell death. A combination therapy of low-dose TZD and BX activated both the PPARγ and RXR receptors reducing PA-induced podocyte damage. This study confirms the crucial role of PPARγ in podocyte biology and that their activation in combination therapy of TZD and BX may be beneficial in the treatment of obesity-related kidney disease.

Original languageEnglish
Article number159329
JournalBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Volume1868
Issue number7
Early online date6 May 2023
DOIs
Publication statusPublished - 1 Jul 2023

Bibliographical note

Funding Information:
Research conducted for this publication was supported by the Mobility stays abroad José Castillejo for young doctors of Ministerio de Educación Cultura y Deporte de España [CAS 12/00160], Ministerio de Economía y Competitividad de España [BFU2016-78951-R, BFU2017-90578-REDT], Ministerio de Ciencia e Innovacion [PID2020-116875RB-I00], Comunidad de Madrid (Spain) [S2017/BMD-3684, P2022/BMD-7227]. RJC was supported by the British Medical Research Council (MRC) with a Senior Clinical Fellowship [MR/K010492/1].Adriana Izquierdo-Lahuerta reports travel was provided by Ministerio de Educación Cultura y Deporte. Gema Medina-Gomez reports financial support was provided by Ministerio de Economía y Competitividad de España. Gema Medina-Gomez reports financial support was provided by Community of Madrid Health Service. Richard J. Coward reports financial support was provided by British Medical Research Council.

Funding Information:
Research conducted for this publication was supported by the Mobility stays abroad José Castillejo for young doctors of Ministerio de Educación Cultura y Deporte de España [CAS 12/00160 ], Ministerio de Economía y Competitividad de España [ BFU2016-78951-R , BFU2017-90578-REDT ], Ministerio de Ciencia e Innovacion [ PID2020-116875RB-I00 ], Comunidad de Madrid (Spain) [ S2017/BMD-3684 , P2022/BMD-7227 ]. RJC was supported by the British Medical Research Council (MRC) with a Senior Clinical Fellowship [ MR/K010492/1 ].

Publisher Copyright:
© 2023 The Authors

Fingerprint

Dive into the research topics of 'The protective role of peroxisome proliferator-activated receptor gamma in lipotoxic podocytes'. Together they form a unique fingerprint.

Cite this